Vimarsana
Biggest News Aggregation in the World

Johan Aschan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Johan Aschan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Johan Aschan Today - Breaking & Trending Today

Sri Lanka Resorts of Cinnamon Hotels & Resorts Mark Earth Day with Impactful Eco-Initiatives - Adaderana Biz English - Vimarsana News

Sri Lanka Resorts of Cinnamon Hotels & Resorts Mark Earth Day with Impactful Eco-Initiatives - Adaderana Biz English

In celebration of Earth Day, Sri Lanka Resorts of Cinnamon Hotels & Resorts conducted a series of impactful initiatives conducted across its eight properties in Sri Lanka, under this year’s global theme of ‘Plastic Vs Planet’. The beach properties of Sri Lanka Resorts, including Cinnamon Bentota Beach, Cinnamon Bey Beruwala, Hikka Tranz by Cinnamon, and...

XNK Therapeutics appoints Dr. Peter Hovstadius as CMO - Vimarsana News

XNK Therapeutics appoints Dr. Peter Hovstadius as CMO

/PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer (CMO), effective immediately. Dr....

XNK Therapeutics AB: XNK Therapeutics appoints Dr. Peter Hovstadius as CMO - Vimarsana News

XNK Therapeutics AB: XNK Therapeutics appoints Dr. Peter Hovstadius as CMO

HUDDINGE, Sweden, Jan. 19, 2023 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer (CMO), effective immediately. Dr.

Positive clinical results of ACP-001 presented at EHA2022 - Vimarsana News

Positive clinical results of ACP-001 presented at EHA2022

/PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its...

XNK Therapeutics AB: Positive clinical results of ACP-001 presented at EHA2022 - Vimarsana News

XNK Therapeutics AB: Positive clinical results of ACP-001 presented at EHA2022

STOCKHOLM, June 10, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate